Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound

Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound


A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. 

Reuters

President Donald Trump on Friday dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound.

But the Centers for Medicare and Medicaid Services said it may reconsider coverage of those drugs in the future, according to a fact sheet on the rule.

The proposal would have given millions more Americans access to those drugs, but would have cost the government billions. Many health plans, including Medicare, don’t currently cover weight loss treatments, and some patients simply can’t afford their hefty price tags before insurance.

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could cost $35 billion over nine years, a congressional analysis found.

Under the Biden administration’s proposal, only those who are considered obese — someone who has a body mass index of 30 or higher — would qualify for coverage. Some people may already get coverage of the drugs through Medicare or Medicaid if they have diabetes or are at risk for stroke or heart disease.

The rule wasn’t finalized before Trump took office.

Novo Nordisk and Eli Lilly did not immediately respond to requests for comment.

Shares of Lilly fell more than 2% in extended trading, while Novo Nordisk’s stock dropped more than 1%.



Source

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Health

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]

Read More
Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug
Health

Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug

Thomas Fuller | SOPA Images | Lightrocket | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer‘s newest bet on obesity is already showing promise.  The company last week said it would buy […]

Read More
Trump, Pfizer to announce agreement to lower Medicaid drug prices
Health

Trump, Pfizer to announce agreement to lower Medicaid drug prices

U.S. President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025. Nathan Howard | Reuters President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices […]

Read More